167 related articles for article (PubMed ID: 36097378)
1. Efficacy and safety of topical brimonidine in dermatology: A review article.
Saki N; Amani M; Nezhad NZ; Shahpar A; Shafiei M; Hosseini SA; Ahramiyanpour N
Dermatol Ther; 2022 Nov; 35(11):e15819. PubMed ID: 36097378
[TBL] [Abstract][Full Text] [Related]
2. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
Lowe E; Lim S
J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
[TBL] [Abstract][Full Text] [Related]
4. Carvedilol ameliorates persistent erythema of erythematotelangiectatic rosacea by regulating the status of anxiety/depression.
Li J; Tang JY; Fu J; Zhang MW; Wan M; Chen DW; Chen QQ; Li X; Song GJ; Ni RR; Song ZQ
J Dermatol; 2022 Nov; 49(11):1139-1147. PubMed ID: 35904063
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
6. Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Okwundu N; Cline A; Feldman SR
J Dermatolog Treat; 2021 Mar; 32(2):137-143. PubMed ID: 31294643
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
8. Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study.
El-Domyati M; Rezk AF; Nasif G; Abdelhameed SS; Medhat W
Int J Dermatol; 2023 Jul; 62(7):888-894. PubMed ID: 37212604
[TBL] [Abstract][Full Text] [Related]
9. Dermatitis medicamentosa: severe rebound erythema secondary to topical brimonidine in rosacea.
Werner K; Kobayashi TT
Dermatol Online J; 2015 Jan; 21(3):. PubMed ID: 25780983
[TBL] [Abstract][Full Text] [Related]
10. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
[TBL] [Abstract][Full Text] [Related]
11. Erythematotelangiectatic rosacea: The combination of 0.5% brimonidine tartrate gel and broadband pulse light therapy to reverse its effects.
Rusina T; Snarskaya E
J Cosmet Dermatol; 2021 Jul; 20(7):2116-2118. PubMed ID: 33179326
[TBL] [Abstract][Full Text] [Related]
12. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea.
Johnson AW; Johnson SM
Dermatol Ther (Heidelb); 2015 Sep; 5(3):171-81. PubMed ID: 26112098
[TBL] [Abstract][Full Text] [Related]
13. A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema.
Agamia N; El-Nagdy S; El-Ariny A
Dermatol Ther; 2022 Apr; 35(4):e15327. PubMed ID: 35060229
[TBL] [Abstract][Full Text] [Related]
14. Medical Management of Facial Redness in Rosacea.
Cline A; McGregor SP; Feldman SR
Dermatol Clin; 2018 Apr; 36(2):151-159. PubMed ID: 29499798
[TBL] [Abstract][Full Text] [Related]
15. Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function.
Bertino B; Blanchet-Réthoré S; Thibaut de Ménonville S; Reynier P; Méhul B; Bogouch A; Gamboa B; Dugaret AS; Zugaj D; Petit L; Roquet M; Piwnica D; Vial E; Bourdès V; Voegel JJ; Nonne C
Exp Dermatol; 2018 Dec; 27(12):1378-1387. PubMed ID: 30290018
[TBL] [Abstract][Full Text] [Related]
16. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
van Zuuren EJ; Fedorowicz Z; Tan J; van der Linden MMD; Arents BWM; Carter B; Charland L
Br J Dermatol; 2019 Jul; 181(1):65-79. PubMed ID: 30585305
[TBL] [Abstract][Full Text] [Related]
17. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
18. S2k guideline: Rosacea.
Clanner-Engelshofen BM; Bernhard D; Dargatz S; Flaig MJ; Gieler U; Kinberger M; Klövekorn W; Kuna AC; Läuchli S; Lehmann P; Nast A; Pleyer U; Schaller M; Schöfer H; Steinhoff M; Schwennesen T; Werner RN; Zierhut M; Reinholz M
J Dtsch Dermatol Ges; 2022 Aug; 20(8):1147-1165. PubMed ID: 35929658
[TBL] [Abstract][Full Text] [Related]
19. Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component.
Micali G; Dall'Oglio F; Verzì AE; Luppino I; Bhatt K; Lacarrubba F
Lasers Med Sci; 2018 Aug; 33(6):1397-1400. PubMed ID: 28889348
[TBL] [Abstract][Full Text] [Related]
20. A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea.
Hofmann MA; Kokolakis G
J Cosmet Laser Ther; 2017 Aug; 19(4):222-224. PubMed ID: 28139145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
